Download full-text PDF |
Source |
|---|
Publication Analysis
Top Keywords
Similar Publications
Unusual case of severe late-onset cytomegalovirus-induced hemorrhagic cystitis and ureteritis in a renal transplant patient.
Ren Fail
May 2012
Division of Nephrology, Department of Internal Medicine, Dokuz Eylul University Hospital, Izmir, Turkey.
Cytomegalovirus (CMV) infection is common in solid organ transplant recipients and accounts for the majority of graft compromise. Major risk factors include primary exposure to CMV infection at the time of transplantation and the use of antilymphocyte agents such as OKT3 (the monoclonal antibody muromonab-CD3) and antithymocyte globulin. It most often develops during the first 6 months after transplantation.
View Article and Find Full Text PDFAnti-lymphocyte therapy successfully controls late "cholestatic" rejection in pediatric liver transplant recipients.
Clin Transplant
May 2012
Department of Surgery, Recanati Miller Transplant Institute, The Mount Sinai School of Medicine, New York, NY 10029, USA.
Rejection is independently associated with liver graft loss in children. We report the successful rescue of grafts using ATG+/-OKT3 in late rejection associated with cholestasis. Retrospective chart review was performed after IRB approval.
View Article and Find Full Text PDFGuidelines for the optimal use of muromonab CD3 in transplantation.
BioDrugs
April 1999
Department of Internal Medicine, Renal Transplant Unit, University of Amsterdam, Amsterdam, The Netherlands.
Muromonab CD3 (OKT3), the murine anti-CD3 monoclonal antibody (mAb) of the IgG-2a class, directed against the CD3 molecule on the surface of human T cells, has proven to be a powerful immunosuppressive agent in solid organ transplantation and has been shown to be superior to high-dose steroids as first-line treatment of acute allograft rejection. It is comparable to antithymocyte globulin (ATG) in treating steroid-resistant rejection and it is also effective as rescue treatment in ATG-resistant rejection. However, OKT3 treatment is followed by a substantial percentage of re-rejections, most of which respond well to steroids.
View Article and Find Full Text PDFInduction immunosuppression is intense, prophylactic therapy used at the time of transplantation based on the empiric observation that more powerful immunosuppression is required to prevent acute rejection early. In the past decade, there has been a growing trend towards the use of specialized agents such as antibody therapies for induction. In general, these agents have been shown to reduce the rate of acute rejection.
View Article and Find Full Text PDFPost-transplantation lymphoproliferative disorder in heart and kidney transplant patients: a single-center experience.
J Cardiovasc Pharmacol Ther
March 2006
Division of Cardiology, University of Missouri-Columbia, Columbia, MO 65212, USA.
Background: Post-transplantation lymphoproliferative disorder (PTLD) after heart transplantation is a fatal complication, and standard treatment is either ineffective or too toxic. We have studied the incidence, clinical course, prognostic factors, and different treatment regimens pertaining to PTLD in 110 heart and 80 kidney transplant recipients.
Methods: Information was abstracted from chart review of 110 heart transplant recipients and 80 kidney transplant recipients between January 1989 and October 2002.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!